Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection (Q42249125)

19 October 2017

title

Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection (English)

1 reference

19 October 2017

K Frenzel

1

1 reference

19 October 2017

J Lehmann

2

1 reference

19 October 2017

D H Krüger

3

1 reference

19 October 2017

L Martin-Parras

4

1 reference

19 October 2017

L Uharek

5

1 reference

19 October 2017

J Hofmann

6

1 reference

19 October 2017

publication date

15 December 2013

1 reference

Medical Microbiology and Immunology

19 October 2017

published in

1 reference

19 October 2017

volume

203

1 reference

19 October 2017

issue

2

1 reference

19 October 2017

page(s)

115-123

1 reference

How we treat cytomegalovirus in hematopoietic cell transplant recipients

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

CMV infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

High genotypic diversity and a novel variant of human cytomegalovirus revealed by combined UL33/UL55 genotyping with broad-range PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Human NK cells can control CMV infection in the absence of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Envelopment of human cytomegalovirus occurs by budding into Golgi-derived vacuole compartments positive for gB, Rab 3, trans-golgi network 46, and mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-013-0321-2

Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H

21 January 2018

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

12 December 2020

Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children

1 reference

12 December 2020

CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.

1 reference

12 December 2020

Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis

1 reference

12 December 2020

Cytomegalovirus immune evasion.

1 reference

12 December 2020

Strain-specific neutralization of human cytomegalovirus isolates by human sera.

1 reference

12 December 2020

Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection

1 reference

12 December 2020

Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies

1 reference

12 December 2020

10.1007/S00430-013-0321-2

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibxbxuuy6fes5ptmezz42kzo4i

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_ibxbxuuy6fes5ptmezz42kzo4i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibxbxuuy6fes5ptmezz42kzo4i

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/ibxbxuuy6fes5ptmezz42kzo4i

1 reference

30 July 2022